Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$68.78
▼ $1.14 (-1.6%)
Market data updated: 09/19 06:24 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$9.56B
Day Range
$68.16 - $70.18
52-Week Range
$47.22 - $88.31
Beta
—
Next Earnings
03.11.2026
Support
$68.15
Resistance
$86.45
CYTK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+39.5% (1Y)
Strengths: 7/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 376.6%
Growth
Biggest negative driver
Operating margin
Operating margin: -695.4% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
40
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
47
Value
50
Momentum
13
Risk
54
Sentiment
80
Fundamental
41
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Cytokinetics’ recent coverage centered on aficamten’s advancing clinical development, highlighted by new Phase 3 data for non‑obstructive hypertrophic cardiomyopathy presented at the 2026 ESC Congress and plans for a supplemental FDA filing. The news also noted substantial insider share sales and the company’s participation in upcoming investor conferences, while the stock faced short‑term pressure despite year‑to‑date gains.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Cytokinetics, Incorporated. News trend score: 80. Reason: 6 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
58
Psychology
82
Fundamentals
41
Technical
13
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-13%
Market Narrative
52
Fundamental Reality
58
Narrative Gap
-6
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **herding** behavior in CYTK reflects a market where participants are aligning with peer group movements, despite mixed technical signals. The negative momentum and peer correlation suggest traders may be following broader sector trends rather than independent analysis. High sentiment scores contrast with weak price action, hinting at potential disconnect between narrative and reality. The key question is whether this synchronization will persist or if divergence emerges as fundamentals or external catalysts shift.
Updated: 09/09/2026, 02:59 PM
What could change this?
👥 What the crowd believes
"positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy"
"plans for a supplemental FDA filing"
"Cytokinetics shares have been under pressure... with the 7 day share price return down 8.46%"
"Cytokinetics Insider Sold Shares Worth $357,400"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Thorstein Veblen — 27/100
🗣️ Why do they disagree?
Based on his documented principles, the model estimates that Benjamin Graham’s defensive approach gives CYTK a perfect score of 100, while his enterprising framework lacks enough valuation data to form a clear view. Meanwhile, Samuel Armstrong Nelson and Walter Bagehot highlight a favorable cycle position and strong liquidity, respectively, pushing the stock into the mid‑70s range, whereas Charles Mackay sees no crowd‑mania signs, keeping it above the 70 threshold. Investors such as Howard Marks, Peter Lynch, and the efficient‑market perspective assign lower scores (58–42) because they view the stock as mixed, priced for growth, or only marginally better than a broad index. Finally, more speculative lenses (Fisher, Veblen, Housel, Livermore) produce sharply lower scores, reflecting concerns about lacking quality, excessive growth for its own sake, volatility that can shake patient holders, and a negative trend that contradicts Livermore’s rule of trading with the market.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 80
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 80
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 65
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 62
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 45
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 34
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 27
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 27
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-695.4%
Net Margin
-891.6%
EBITDA Margin
-683.9%
ROE
119.0%
ROA
-55.1%
ROIC
—
EPS
-$6.54
Cash
$122.52M
Total Debt
$287.56M
Current Ratio
4.53
Debt/Equity
-0.44
How is Fair Value calculated? →
Current Price
$68.78
Estimated Fair Value (DCF)
-$114,996.39
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-668.52M | $-613.32M |
| 2 | 19.4% | $-798.05M | $-671.70M |
| 3 | 13.8% | $-907.78M | $-700.97M |
| 4 | 8.1% | $-981.53M | $-695.34M |
| 5 | 2.5% | $-1.01B | $-653.88M |
Base FCF (last actual year)
$-534.82M
Terminal Value
$-15.86B
Present Value of Terminal Value
$-10.31B
Enterprise Value
$-13.65B
Net Debt
$165.05M
Equity Value
$-13.81B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$5,492.16
Tangible Book Value per Share (Tangible NAV)
-$5,492.16
Sentiment based on basic keywords (not AI) — 6 positive, 13 neutral, 1 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 14.9.2026
SeekingAlpha · 14.9.2026
Benzinga · 11.9.2026
Yahoo · 10.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 8.9.2026
Insider Monkey · 8.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
MT Newswires · 1.9.2026
Yahoo · 1.9.2026
Simply Wall St. · 1.9.2026
Yahoo · 1.9.2026
Simply Wall St. · 1.9.2026
MT Newswires · 31.8.2026
Benzinga · 31.8.2026
Cytokinetics, Incorporated (CYTK) currently has a StockIQ AI score of 40/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
CYTK currently scores 40/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
CYTK's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 376.6%; Return on equity (ROE): 119.0% — strong; Debt/equity: -0.44.
Based on the real signals StockIQ computed: Operating margin: -695.4% (negative); Net margin: -891.6% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for CYTK.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 9 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Malik Fady Ibraham | Open Market Sale | 8.9.2026 | 3,500 | -3,500 | $75.46 |
| Malik Fady Ibraham | Exercise of Derivative Securities | 8.9.2026 | 3,500 | +3,500 | $7.80 |
| Malik Fady Ibraham | Exercise of Derivative Securities | 8.9.2026 | 3,500 | -3,500 | — |
| PARSHALL B LYNNE | Open Market Sale | 1.9.2026 | 5,000 | -5,000 | $71.48 |
| Blum Robert I | Exercise of Derivative Securities | 31.8.2026 | 7,500 | +7,500 | $10.60 |
| Callos Andrew | Open Market Sale | 31.8.2026 | 10,000 | -10,000 | $70.24 |
| Blum Robert I | Exercise of Derivative Securities | 31.8.2026 | 7,500 | -7,500 | — |
| Blum Robert I | Open Market Sale | 31.8.2026 | 7,500 | -7,500 | $70.24 |
| Callos Andrew | Exercise of Derivative Securities | 31.8.2026 | 10,000 | +10,000 | $23.26 |
| Callos Andrew | Exercise of Derivative Securities | 31.8.2026 | 10,000 | -10,000 | — |
| Blum Robert I | Exercise of Derivative Securities | 31.8.2026 | 164,245 | -7,500 | — |
| Callos Andrew | Exercise of Derivative Securities | 31.8.2026 | 68,555 | +10,000 | $23.26 |
| Blum Robert I | Open Market Sale | 31.8.2026 | 377,820 | -7,500 | $70.24 |
| Blum Robert I | Exercise of Derivative Securities | 31.8.2026 | 385,320 | +7,500 | $10.60 |
| Callos Andrew | Exercise of Derivative Securities | 31.8.2026 | 0 | -10,000 | — |
| Callos Andrew | Open Market Sale | 31.8.2026 | 58,555 | -10,000 | $70.24 |
| Malik Fady Ibraham | Exercise of Derivative Securities | 18.8.2026 | 3,500 | -3,500 | — |
| Malik Fady Ibraham | Exercise of Derivative Securities | 18.8.2026 | 3,500 | +3,500 | $7.80 |
| Malik Fady Ibraham | Open Market Sale | 18.8.2026 | 3,500 | -3,500 | $75.82 |
| Blum Robert I | Open Market Sale | 10.8.2026 | 7,500 | -7,500 | $76.76 |
| Blum Robert I | Exercise of Derivative Securities | 10.8.2026 | 7,500 | +7,500 | $10.60 |
| Blum Robert I | Exercise of Derivative Securities | 10.8.2026 | 7,500 | -7,500 | — |
| Callos Andrew | Exercise of Derivative Securities | 30.7.2026 | 14,000 | -14,000 | — |
| Callos Andrew | Open Market Sale | 30.7.2026 | 14,000 | -14,000 | $79.88 |
| Callos Andrew | Exercise of Derivative Securities | 30.7.2026 | 14,000 | +14,000 | $23.26 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
17,442,378 shares short as of 2026-08-31 · vs. 15,303,504 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
46.5% of trading volume this week was short selling, vs. 60.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology